health-and-wellness U.S. Food and Drug Administration (FDA) grants rapid development approval to the Experimental Drug Centre for their Antibody-Drug Conjugate, EBC-129, aimed at combatting Pancreatic Ductal Adenocarcinoma. , and Administrator 2025 May 30
